REG - Eco Animal Health Gp - Director/PDMR Dealing

ECO Animal HealthAnnouncement

23/03/2022 18:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220323:nRSW8223Fa&default-theme=true

RNS Number : 8223F  Eco Animal Health Group PLC  23 March 2022

ECO Animal Health Group plc

(''ECO", the "Company" or the "ECO Group") (AIM: EAH)

 

Director/PDMR Dealings

 

ECO Animal Health Group plc, a leader in the development, registration and
marketing of pharmaceutical products for global animal health markets, has
been notified that on 23 March 2022, Christopher Wilks, Chief Financial
Officer, purchased 25,000 Ordinary Shares of 5 pence each ("Ordinary Shares")
at a price of 160 pence per share.

 

Following this transaction, Christopher Wilks' total interest in the Company
is 99,095 Ordinary Shares, representing approximately 0.15 per cent. of the
Company's issued share capital.

 

Details of the transactions can be found in the Notification of Dealing Form
below.

 

 

For further information please contact:

                                                                020 8447 8899

 ECO Animal Health Group plc

 Marc Loomes (CEO)

 Christopher Wilks (CFO)

 IFC Advisory                                                   020 3934 6630

 Graham Herring

 Zach Cohen

 Singer Capital Markets (Nominated Adviser & Joint Broker)      020 7496 3000

 Mark Taylor

 George Tzimas

 Investec (Joint Broker)                                        020 7597 5970

 Gary Clarence

 Alex Penney

 Carlo Spingardi

 Peel Hunt LLP (Joint Broker)                                   020 7418 8900

 Dr Christopher Golden

 James Steel

 

 Equity Developments  020 7065 2692

 Hannah Crowe

 Matt Evans

 

 

About ECO Animal Health

ECO Animal Health Group plc researches, develops and commercialises products
for livestock. Our business strategy is to generate shareholder value by
achieving the maximum sales potential from the existing product portfolio
whilst investing in Research and Development ("R&D") for new products,
particularly vaccines, and seeking to in-license new products.

 

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Christopher Wilks

 2    Reason for the notification

 a)   Position/status                                              Chief Financial Officer

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         ECO Animal Health Group plc

 b)   LEI                                                          2138009XN9DJ3YP70B55

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary shares of 5 pence each

      Identification code                                          GB0032036807

 b)   Nature of the transaction                                    Purchase of Ordinary Shares

 c)   Price(s) and volume(s)

                                                                                     Price(s)          Volume(s)
                                                                                     160 pence         25,000

 d)   Aggregated information                                       N/A - Single transaction

      - Aggregated volume

      - Price

 e)   Date of the transaction                                      23 March 2022

 f)   Place of the transaction                                     London Stock Exchange, AIM

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHUOVBRUAUOUAR